Literature DB >> 23238855

Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo.

K H Williams1, N A Shackel, M D Gorrell, S V McLennan, S M Twigg.   

Abstract

Recent data increasingly support a complex interplay between the metabolic condition diabetes mellitus and the pathologically defined nonalcoholic fatty liver disease (NAFLD). NAFLD predicts the development of type 2 diabetes and vice versa, and each condition may serve as a progression factor for the other. Although the association of diabetes and NAFLD is likely to be partly the result of a "common soil," it is also probable that diabetes interacts with NAFLD through specific pathogenic mechanisms. In particular, through interrelated metabolic pathways currently only partly understood, diabetes appears to accelerate the progression of NAFLD to nonalcoholic steatohepatitis, defined by the presence of necroinflammation, with varying degrees of liver fibrosis. In the research setting, obstacles that have made the identification of clinically significant NAFLD, and particularly nonalcoholic steatohepatitis, difficult are being addressed with the use of new imaging techniques combined with risk algorithms derived from peripheral blood profiling. These techniques are likely to be used in the diabetes population in the near future. This review examines the pathogenic links between NAFLD and diabetes by exploring the epidemiological evidence in humans and also through newer animal models. Emerging technology to help screen noninvasively for differing pathological forms of NAFLD and the potential role of preventive and therapeutic approaches for NAFLD in the setting of diabetes are also examined.

Entities:  

Mesh:

Year:  2012        PMID: 23238855     DOI: 10.1210/er.2012-1009

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  78 in total

1.  Shedding Perspective on Extracellular Vesicle Biology in Diabetes and Associated Metabolic Syndromes.

Authors:  Naureen Javeed
Journal:  Endocrinology       Date:  2019-02-01       Impact factor: 4.736

2.  Predicting hepatic steatosis in a racially and ethnically diverse cohort of adolescent girls.

Authors:  Jennifer L Rehm; Ellen L Connor; Peter M Wolfgram; Jens C Eickhoff; Scott B Reeder; David B Allen
Journal:  J Pediatr       Date:  2014-05-22       Impact factor: 4.406

3.  Serum transforming growth factor beta 3 predicts future development of nonalcoholic fatty liver disease.

Authors:  Yongli Wei; Qing Tian; Xiuxia Zhao; Xingchun Wang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 4.  Type 2 diabetes mellitus and osteoarthritis.

Authors:  Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen
Journal:  Semin Arthritis Rheum       Date:  2019-01-11       Impact factor: 5.532

Review 5.  Epidemiology of fatty liver: an update.

Authors:  Giorgio Bedogni; Valerio Nobili; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 6.  Nonalcoholic fatty liver disease and cardiovascular disease.

Authors:  Hong Liu; Hong-Yun Lu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

7.  Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study.

Authors:  Nadia Pallotta; Tiziana Filardi; Anna Carnovale; Luciano Nieddu; Paola Mariani; Giuseppina Vincoli; Andrea Lenzi; Susanna Morano
Journal:  Endocrine       Date:  2016-07-15       Impact factor: 3.633

Review 8.  Immune cells and metabolic dysfunction.

Authors:  Ashley Eheim; Dasa Medrikova; Stephan Herzig
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

9.  Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Geraldine J Ooi; Paul R Burton; Lisa Doyle; John M Wentworth; Prithi S Bhathal; Ken Sikaris; Michael A Cowley; Stuart K Roberts; William Kemp; Arul Earnest; Paul E O'Brien; Wendy A Brown
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

10.  Novel curcumin derivative CNB-001 mitigates obesity-associated insulin resistance.

Authors:  Evgeniy Panzhinskiy; Yinan Hua; Paul A Lapchak; Elena Topchiy; Teresa E Lehmann; Jun Ren; Sreejayan Nair
Journal:  J Pharmacol Exp Ther       Date:  2014-02-18       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.